TRCT
DRUG

Tower Research Capital (TRC)’s Bright Minds Biosciences DRUG Stock Holding History

Tower Research Capital (TRC)’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43.6K Sell
597
-485
-45% -$39K ﹤0.01% 2868
2025
Q4 		$84.4K Buy
1,082
+811
+299% +$54.2K ﹤0.01% 2050
2025
Q3 		$16.4K Buy
+271
New +$10.5K ﹤0.01% 3476
2022
Q4 		– Sell
-126
Closed -$1K – 5974
2022
Q3 		$1K Buy
+126
New +$817 ﹤0.01% 5753

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Tower Research Capital (TRC)'s DRUG Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Bright Minds Biosciences (DRUG) stake by 45% in Q1 2026, selling an estimated $39K and leaving 597 shares worth $43.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2868.

Tower Research Capital (TRC) first reported a position in DRUG in Q3 2022 and has held it in 4 quarters since. The position peaked at $84.4K in Q4 2025. 94 funds tracked by Wall St. Rank hold DRUG as of Q1 2026.

  • Tower Research Capital (TRC) held 597 shares of Bright Minds Biosciences worth $43.6K as of Q1 2026.
  • Tower Research Capital (TRC) sold 485 Bright Minds Biosciences shares in Q1 2026, an estimated $39K.
  • Bright Minds Biosciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2868 holding.
  • Tower Research Capital (TRC) first reported a position in Bright Minds Biosciences in Q3 2022 and has held it in 4 quarters since.
  • Tower Research Capital (TRC)'s Bright Minds Biosciences position peaked at $84.4K in Q4 2025.
  • 94 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.